Diamyd Medical Achieves Patent Milestone for Retogatein
Diamyd Medical has reached an important milestone in its journey towards advancing treatments for type 1 diabetes. The United States Patent and Trademark Office has granted a Notice of Allowance for a crucial patent focused on the intralymphatic administration of retogatein (rhGAD65) combined with alum. This breakthrough represents a significant step forward for Diamyd Medical as it enhances its immunotherapy platform aimed at preventing and treating this challenging illness.
Patent Importance and Global Reach
This allowed U.S. application is a part of a broader patent family, which already boasts protections in various regions including Europe, Australia, Hong Kong, China, Canada, South Africa, Japan, Russia, and Israel. The acquisition of U.S. patent rights will further solidify Diamyd Medical's international patent framework, safeguarding its innovations until approximately 2035.
Ulf Hannelius, the President and CEO of Diamyd Medical, expressed the company's excitement about this development, stating, "This Notice of Allowance further strengthens our global intellectual property for our precision medicine and antigen-specific immunotherapy in type 1 diabetes. Securing patent protection in the U.S. is a key milestone as retogatein advances toward potential commercialization."
Clinical Trials and Future Prospects
The patented method of intralymphatic administration is actively utilized in the ongoing Phase 3 DIAGNODE-3 trial, which examines children, adolescents, and adults recently diagnosed with type 1 diabetes. An interim efficacy readout that aligns with FDA standards is expected by the end of March 2026, adding anticipation around this therapy's potential.
Retogatein is recognized as a biological product and is thus eligible for regulatory market exclusivity in both the United States and Europe, independent of patent protections, contingent upon regulatory approval. This regulatory pathway underscores the company's commitment to bringing innovative treatments to market effectively.
About Diamyd Medical's Innovative Therapies
Diamyd Medical is dedicated to developing precision medicine therapies that specifically target the prevention and treatment of type 1 diabetes. The investigational product retogatein, formulated with alum, is designed as an antigen-specific immunotherapy with the goal of inducing immune tolerance to GAD65, ultimately preserving the body's ability to produce insulin for those carrying the HLA DR3-DQ2 gene.
In the U.S., retogatein has been granted Orphan Drug Designation, alongside Fast Track Designation for treating both Stage 3 type 1 diabetes and earlier stages in patients who are pre-symptomatic. The DIAGNODE-3 trial is currently ongoing across 57 clinics in eight European countries and the U.S., focusing on patients with Stage 3 type 1 diabetes onset. Previous studies have shown promising results in maintaining endogenous insulin production within genetically predefined groups of patients.
Future Developments at Diamyd Medical
The company is also establishing a biomanufacturing facility in Umeå, Sweden, dedicated to producing retogatein, the active component in their immunotherapy. With its strategic initiatives, Diamyd Medical demonstrates its commitment to innovation in treatment for type 1 diabetes while positioning itself for growth within the biotechnology landscape.
Furthermore, Diamyd Medical holds significant stakes in NextCell Pharma AB and MainlyAI AB, highlighting its diverse engagement within the biotechnology sector.
For Further Information
For additional information regarding these developments or inquiries, please connect with Ulf Hannelius, President and CEO. Reach out via phone at +46 736 35 42 41.
Frequently Asked Questions
What is the significance of the Notice of Allowance?
The Notice of Allowance signifies that the U.S. Patent and Trademark Office has granted preliminary approval for a patent crucial to Diamyd Medical's treatments.
What therapy does the patent cover?
The patent covers the intralymphatic administration of retogatein, which is integral to the treatment of type 1 diabetes.
Where else is the patent protected?
The patent is part of a family of rights granted across multiple countries, including regions in Europe, Australia, and Asia.
What is the expected outcome of the ongoing clinical trials?
The ongoing DIAGNODE-3 trial aims to provide further efficacy data for retogatein and its ability to maintain insulin production in diabetic patients.
How is Diamyd Medical approaching future treatments?
The company is dedicated to precision medicine, enhancing treatment efficacy and safety for individuals with type 1 diabetes while expanding its market footprint.
